Ceftazidime Injection — FDA Drug Shortage

To Be Discontinued — Hospira, Inc., A Pfizer Company

The FDA lists a drug shortage record for Ceftazidime Injection (injection) from Hospira, Inc., A Pfizer Company with status To Be Discontinued. The shortage was first posted on Nov 14, 2025.

Shortage details

Status
To Be Discontinued
Company
Hospira, Inc., A Pfizer Company
Package NDC
0409-5092-16
Dosage Form
Injection
Presentation
Tazicef, Injection, 1 g (NDC 0409-5092-16)
Initial Posting
Nov 14, 2025

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.